SEMAGLUTIDES THICKET OF FOLLOW-ON PATENTS In addition to the patents protecting the compound semaglutide and its derivative forms, Novo Nordisk has built a considerable patent thicket of follow-on patents
The absence of warnings or other information for a particular medication does not imply that the medication or medication combination is appropriate for all patients or for all possible purposes.
We see from a study on factors related to the secretion of this hormone that the components of a meal act as potent stimulants of GLP-1 secretion, and the levels of its secretion change with the intake of different nutrients (1)
Coverage requirements typically include BMI over 30 (or over 27 with comorbidities), documented failed lifestyle interventions, physician letter of medical necessity, and ongoing monitoring
Molecular mechanisms of ischemic cerebral edema: role of electroneutral ion transport
A 2021 study reported that Ozempic use increased the risk of deep vein thrombosis (DVT), a condition caused by blood clotting deep in the body